Evidence map›Paper›PMID 33748895›Full record

ArticleAnnals of surgical oncology2021

Patient-Derived Tumor Xenografts Plus Ex Vivo Models Enable Drug Validation for Tenosynovial Giant Cell Tumors.

Fan Tang, Yan Tie, Wei-Qi Hong, Xin He, Li Min, Yong Zhou, Yi Luo, Si-Yuan Chen, Jing-Yun Yang, Hou-Hui Shi and 2 more

Abstract read
PubMed Publisher
In one paragraph

Article in Annals of surgical oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

12 authors.

Fan TangDepartment of Orthopedics, Orthopedic Research Institute, West China Hospital, Sichuan University, Chengdu, China.
Yan TieSichuan Cancer Hospital and Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China.
Wei-Qi HongLaboratory of Aging Research and Cancer Drug Target, State Key Laboratory of Biotherapy, National Clinical Research Center for Geriatrics, West China Hospital, Sichuan University, Chengdu, China.
Xin HeDepartment of Pathology, West China Hospital, Sichuan University, Chengdu, China.
Li MinDepartment of Orthopedics, Orthopedic Research Institute, West China Hospital, Sichuan University, Chengdu, China.
Yong ZhouDepartment of Orthopedics, Orthopedic Research Institute, West China Hospital, Sichuan University, Chengdu, China.
Yi LuoDepartment of Orthopedics, Orthopedic Research Institute, West China Hospital, Sichuan University, Chengdu, China.
Si-Yuan ChenLaboratory of Aging Research and Cancer Drug Target, State Key Laboratory of Biotherapy, National Clinical Research Center for Geriatrics, West China Hospital, Sichuan University, Chengdu, China.
Jing-Yun YangLaboratory of Aging Research and Cancer Drug Target, State Key Laboratory of Biotherapy, National Clinical Research Center for Geriatrics, West China Hospital, Sichuan University, Chengdu, China.
Hou-Hui ShiLaboratory of Aging Research and Cancer Drug Target, State Key Laboratory of Biotherapy, National Clinical Research Center for Geriatrics, West China Hospital, Sichuan University, Chengdu, China.
Xia-Wei WeiLaboratory of Aging Research and Cancer Drug Target, State Key Laboratory of Biotherapy, National Clinical Research Center for Geriatrics, West China Hospital, Sichuan University, Chengdu, China. xiaweiwei@scu.edu.cn.
Chong-Qi TuDepartment of Orthopedics, Orthopedic Research Institute, West China Hospital, Sichuan University, Chengdu, China. tcq_orthoncologist@163.com.

Funding

China Postdoctoral Science Foundation 2020T130447Excellent Youth Foundation of Sichuan Scientific Committee Grant in China 2019JDJQ008Key Programs of Sichuan Scientific Committee Grant in China 2020YFS0144National Natural Science Foundation of China 82002847
6 · The paper itself

Abstract

introductionTenosynovial giant cell tumor (TGCT) is a locally aggressive tumor with colony-stimulating factor 1 receptor (CSF1R) signal expression. However, there is a lack of better in vivo and ex vivo models for TGCT. This study aims to establish a favorable preclinical translational platform, which would enable the validation of efficient and personalized therapeutic candidates for TGCT. PATIENTS AND

methodsHistological analyses were performed for the included patients. Fresh TGCT tumors were collected and sliced into 1.0-3.0 mm

resultsThe TGCT tumor grafts that were implanted into athymic mice subrenal capsules maintained their original morphological and histological features. The "take" rate of this model was 95% (19/20). Administration of CSF1R inhibitors (PLX3397, and a novel candidate, WXFL11420306) to TGCT-PDTX mice was shown to reduce tumor size while inducing intratumoral apoptosis. In addition, the CSF1R inhibitors suppressed circulating nonspecific monocyte levels and CD163-positive cells within tumors. These response patterns of engrafts to PDTX were validated by ex vivo PDE cultures.

conclusionsSubrenal capsule supports the growth of TGCT tumor grafts, maintaining their original morphology and histology. This TGCT-PDTX model plus ex vivo explant cultures is a potential preclinical translational platform for locally aggressive tumors, such as TGCT.

Indexed as

Antineoplastic AgentsGiant Cell Tumor of Tendon SheathPharmaceutical PreparationsAnimalsHeterograftsHumansMiceAntineoplastic AgentsPharmaceutical Preparations

Identifiers

PMID33748895

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.